{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:16:59Z","timestamp":1791411419969,"version":"4.3.3"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"50","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2014,12,11]]},"DOI":"10.1038\/onc.2013.565","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T13:40:17Z","timestamp":1390830017000},"page":"5655-5665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Mechanisms and consequences of constitutive NF-\u03baB activation in B-cell lymphoid malignancies"],"prefix":"10.1038","volume":"33","author":[{"given":"D","family":"Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vincendeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C","family":"Eitelhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Krappmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"BFonc2013565_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-biophys-083012-130338","volume":"42","author":"J Napetschnig","year":"2013","unstructured":"Napetschnig J, Wu H . Molecular basis of NF-kappaB signaling. Annu Rev Biophys 2013; 42: 443\u2013468.","journal-title":"Annu Rev Biophys"},{"key":"BFonc2013565_CR2","doi-asserted-by":"publisher","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus A, Ghosh S . The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009; 1: a000034.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFonc2013565_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1600-065X.2012.01098.x","volume":"246","author":"N Kanarek","year":"2012","unstructured":"Kanarek N, Ben-Neriah Y . Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev 2012; 246: 77\u201394.","journal-title":"Immunol Rev"},{"key":"BFonc2013565_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1101\/gad.183434.111","volume":"26","author":"MS Hayden","year":"2012","unstructured":"Hayden MS, Ghosh S . NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203\u2013234.","journal-title":"Genes Dev"},{"key":"BFonc2013565_CR5","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1038\/sj.onc.1209934","volume":"25","author":"C Scheidereit","year":"2006","unstructured":"Scheidereit C . IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006; 25: 6685\u20136705.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S . Shared principles in NF-kappaB signaling. Cell 2008; 132: 344\u2013362.","journal-title":"Cell"},{"key":"BFonc2013565_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC . Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21: 71\u201385.","journal-title":"Cell Res"},{"key":"BFonc2013565_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS . Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265\u2013276.","journal-title":"Blood"},{"key":"BFonc2013565_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.184.4.1495","volume":"184","author":"H Kanzler","year":"1996","unstructured":"Kanzler H, Kuppers R, Hansmann ML, Rajewsky K . Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184: 1495\u20131505.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","volume":"95","author":"T Marafioti","year":"2000","unstructured":"Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95: 1443\u20131450.","journal-title":"Blood"},{"key":"BFonc2013565_CR11","first-page":"1644","volume":"63","author":"A Brauninger","year":"2003","unstructured":"Brauninger A, Wacker HH, Rajewsky K, Kuppers R, Hansmann ML . Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res 2003; 63: 1644\u20131651.","journal-title":"Cancer Res"},{"key":"BFonc2013565_CR12","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1182\/blood.V87.10.4340.bloodjournal87104340","volume":"87","author":"RC Bargou","year":"1996","unstructured":"Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin\/Reed-Sternberg cells. Blood 1996; 87: 4340\u20134347.","journal-title":"Blood"},{"key":"BFonc2013565_CR13","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1172\/JCI119849","volume":"100","author":"RC Bargou","year":"1997","unstructured":"Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961\u20132969.","journal-title":"J Clin Invest"},{"key":"BFonc2013565_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.onc.1202351","volume":"18","author":"D Krappmann","year":"1999","unstructured":"Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C . Molecular mechanisms of constitutive NF-kappaB\/Rel activation in Hodgkin\/Reed-Sternberg cells. Oncogene 1999; 18: 943\u2013953.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1084\/jem.20020062","volume":"196","author":"M Hinz","year":"2002","unstructured":"Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, Mathas S et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196: 605\u2013617.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","volume":"4","author":"R Schmitz","year":"2009","unstructured":"Schmitz R, Stanelle J, Hansmann ML, Kuppers R . Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4: 151\u2013174.","journal-title":"Annu Rev Pathol"},{"key":"BFonc2013565_CR17","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1182\/blood.V94.9.3129","volume":"94","author":"F Emmerich","year":"1999","unstructured":"Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129\u20133134.","journal-title":"Blood"},{"key":"BFonc2013565_CR18","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/jcp.2007.050146","volume":"60","author":"G Kapatai","year":"2007","unstructured":"Kapatai G, Murray P . Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 2007; 60: 1342\u20131349.","journal-title":"J Clin Pathol"},{"key":"BFonc2013565_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1600-065X.2010.00932.x","volume":"237","author":"JP Graham","year":"2010","unstructured":"Graham JP, Arcipowski KM, Bishop GA . Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 2010; 237: 226\u2013248.","journal-title":"Immunol Rev"},{"key":"BFonc2013565_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2478\/s11658-008-0045-2","volume":"14","author":"MF Pang","year":"2009","unstructured":"Pang MF, Lin KW, Peh SC . The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer. Cell Mol Biol Lett 2009; 14: 222\u2013247.","journal-title":"Cell Mol Biol Lett"},{"key":"BFonc2013565_CR21","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/emboj\/17.6.1700","volume":"17","author":"E Kilger","year":"1998","unstructured":"Kilger E, Kieser A, Baumann M, Hammerschmidt W . Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998; 17: 1700\u20131709.","journal-title":"EMBO J"},{"key":"BFonc2013565_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1073\/pnas.2237183100","volume":"101","author":"M Luftig","year":"2004","unstructured":"Luftig M, Yasui T, Soni V, Kang MS, Jacobson N, Cahir-McFarland E et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK\/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci USA 2004; 101: 141\u2013146.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR23","doi-asserted-by":"publisher","first-page":"7557","DOI":"10.1038\/sj.onc.1207120","volume":"22","author":"AG Eliopoulos","year":"2003","unstructured":"Eliopoulos AG, Caamano JH, Flavell J, Reynolds GM, Murray PG, Poyet JL et al. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma\/NEMO-independent signalling pathway. Oncogene 2003; 22: 7557\u20137569.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR24","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.1073\/pnas.95.20.11963","volume":"95","author":"W Kulwichit","year":"1998","unstructured":"Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N . Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998; 95: 11963\u201311968.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1126\/science.286.5438.300","volume":"286","author":"J Uchida","year":"1999","unstructured":"Uchida J, Yasui T, Takaoka-Shichijo Y, Muraoka M, Kulwichit W, Raab-Traub N et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999; 286: 300\u2013303.","journal-title":"Science"},{"key":"BFonc2013565_CR26","doi-asserted-by":"crossref","unstructured":"Mao Y, Lu MP, Lin H, Zhang da W, Liu Y, Li QD et al. Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies. PloS One 2013; 8: doi doi:10.1371 e60313.","DOI":"10.1371\/journal.pone.0060313"},{"key":"BFonc2013565_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1006\/viro.1997.8690","volume":"235","author":"S Fruehling","year":"1997","unstructured":"Fruehling S, Longnecker R . The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 1997; 235: 241\u2013251.","journal-title":"Virology"},{"key":"BFonc2013565_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","volume":"9","author":"RG Caldwell","year":"1998","unstructured":"Caldwell RG, Wilson JB, Anderson SJ, Longnecker R . Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9: 405\u2013411.","journal-title":"Immunity"},{"key":"BFonc2013565_CR29","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1182\/blood-2007-05-090142","volume":"110","author":"C Mancao","year":"2007","unstructured":"Mancao C, Hammerschmidt W . Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007; 110: 3715\u20133721.","journal-title":"Blood"},{"key":"BFonc2013565_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ni1036","volume":"5","author":"S Casola","year":"2004","unstructured":"Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004; 5: 317\u2013327.","journal-title":"Nat Immunol"},{"key":"BFonc2013565_CR31","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","volume":"101","author":"I Schwering","year":"2003","unstructured":"Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101: 1505\u20131512.","journal-title":"Blood"},{"key":"BFonc2013565_CR32","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1182\/blood-2005-09-3765","volume":"107","author":"A Ushmorov","year":"2006","unstructured":"Ushmorov A, Leithauser F, Sakk O, Weinhausel A, Popov SW, Moller P et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107: 2493\u20132500.","journal-title":"Blood"},{"key":"BFonc2013565_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1080\/10428190701784722","volume":"49","author":"D Re","year":"2008","unstructured":"Re D, Hartlapp I, Greiner A, Diehl V, Wickenhauser C . Analysis of CARMA1\/BCL10\/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma. Leuk Lymphoma 2008; 49: 362\u2013364.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2013565_CR34","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1182\/blood.V99.4.1474","volume":"99","author":"JI Martin-Subero","year":"2002","unstructured":"Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002; 99: 1474\u20131477.","journal-title":"Blood"},{"key":"BFonc2013565_CR35","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1182\/blood-2002-08-2577","volume":"101","author":"TF Barth","year":"2003","unstructured":"Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 2003; 101: 3681\u20133686.","journal-title":"Blood"},{"key":"BFonc2013565_CR36","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1182\/blood.V99.4.1381","volume":"99","author":"S Joos","year":"2002","unstructured":"Joos S, Menz CK, Wrobel G, Siebert R, Gesk S, Ohl S et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002; 99: 1381\u20131387.","journal-title":"Blood"},{"key":"BFonc2013565_CR37","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2004-09-3620","volume":"106","author":"S Mathas","year":"2005","unstructured":"Mathas S, Johrens K, Joos S, Lietz A, Hummel F, Janz M et al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005; 106: 4287\u20134293.","journal-title":"Blood"},{"key":"BFonc2013565_CR38","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1101\/gad.7.7b.1354","volume":"7","author":"T Fujita","year":"1993","unstructured":"Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D . The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes dev 1993; 7: 1354\u20131363.","journal-title":"Genes dev"},{"key":"BFonc2013565_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2005-09-3843","volume":"108","author":"JI Martin-Subero","year":"2006","unstructured":"Martin-Subero JI, Wlodarska I, Bastard C, Picquenot JM, Hoppner J, Giefing M et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. Blood 2006; 108: 401\u2013402 author reply 402-403.","journal-title":"Blood"},{"key":"BFonc2013565_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.191.2.395","volume":"191","author":"B Jungnickel","year":"2000","unstructured":"Jungnickel B, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, Diehl V et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395\u2013402.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR41","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ijc.24502","volume":"125","author":"A Lake","year":"2009","unstructured":"Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S et al. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer 2009; 125: 1334\u20131342.","journal-title":"Int J Cancer"},{"key":"BFonc2013565_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/path.1454","volume":"201","author":"F Emmerich","year":"2003","unstructured":"Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS, Dohner K et al. Inactivating I kappa B epsilon mutations in Hodgkin\/Reed-Sternberg cells. J Pathol 2003; 201: 413\u2013420.","journal-title":"J Pathol"},{"key":"BFonc2013565_CR43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nature07969","volume":"459","author":"M Kato","year":"2009","unstructured":"Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712\u2013716.","journal-title":"Nature"},{"key":"BFonc2013565_CR44","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1084\/jem.20090528","volume":"206","author":"R Schmitz","year":"2009","unstructured":"Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981\u2013989.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.it.2009.05.007","volume":"30","author":"L Vereecke","year":"2009","unstructured":"Vereecke L, Beyaert R, van Loo G . The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30: 383\u2013391.","journal-title":"Trends Immunol"},{"key":"BFonc2013565_CR46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/gcc.20789","volume":"49","author":"A Schmidt","year":"2010","unstructured":"Schmidt A, Schmitz R, Giefing M, Martin-Subero JI, Gesk S, Vater I et al. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer 2010; 49: 803\u2013809.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2013565_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-065X.2012.01100.x","volume":"246","author":"EW Harhaj","year":"2012","unstructured":"Harhaj EW, Dixit VM . Regulation of NF-kappaB by deubiquitinases. Immunol Rev 2012; 246: 107\u2013124.","journal-title":"Immunol Rev"},{"key":"BFonc2013565_CR48","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1038\/sj.onc.1208564","volume":"24","author":"M Nonaka","year":"2005","unstructured":"Nonaka M, Horie R, Itoh K, Watanabe T, Yamamoto N, Yamaoka S . Aberrant NF-kappaB2\/p52 expression in Hodgkin\/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 2005; 24: 3976\u20133986.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR49","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood-2012-01-405951","volume":"120","author":"SM Ranuncolo","year":"2012","unstructured":"Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES, Lewis BA . Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 2012; 120: 3756\u20133763.","journal-title":"Blood"},{"key":"BFonc2013565_CR50","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2141.2012.09113.x","volume":"157","author":"C Otto","year":"2012","unstructured":"Otto C, Giefing M, Massow A, Vater I, Gesk S, Schlesner M et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012; 157: 702\u2013708.","journal-title":"Br J Haematol"},{"key":"BFonc2013565_CR51","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa064601","volume":"357","author":"C Ferme","year":"2007","unstructured":"Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916\u20131927.","journal-title":"N Engl J Med"},{"key":"BFonc2013565_CR52","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-11-0467","volume":"17","author":"LM McAllister-Lucas","year":"2011","unstructured":"McAllister-Lucas LM, Baens M, Lucas PC . MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res 2011; 17: 6623\u20136631.","journal-title":"Clin Cancer Res"},{"key":"BFonc2013565_CR53","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrc1409","volume":"4","author":"PG Isaacson","year":"2004","unstructured":"Isaacson PG, Du MQ . MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4: 644\u2013653.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2013565_CR54","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D","volume":"178","author":"T Hussell","year":"1996","unstructured":"Hussell T, Isaacson PG, Crabtree JE, Spencer J . Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122\u2013127.","journal-title":"J Pathol"},{"key":"BFonc2013565_CR55","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1053\/gast.2002.33047","volume":"122","author":"H Liu","year":"2002","unstructured":"Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, Thiede C et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286\u20131294.","journal-title":"Gastroenterology"},{"key":"BFonc2013565_CR56","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0092-8674(00)80957-5","volume":"96","author":"TG Willis","year":"1999","unstructured":"Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35\u201345.","journal-title":"Cell"},{"key":"BFonc2013565_CR57","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0002-9440(10)64630-5","volume":"157","author":"H Ye","year":"2000","unstructured":"Ye H, Dogan A, Karran L, Willis TG, Chen L, Wlodarska I et al. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am J Pathol 2000; 157: 1147\u20131154.","journal-title":"Am J Pathol"},{"key":"BFonc2013565_CR58","doi-asserted-by":"publisher","first-page":"a003004","DOI":"10.1101\/cshperspect.a003004","volume":"2","author":"M Thome","year":"2010","unstructured":"Thome M, Charton JE, Pelzer C, Hailfinger S . Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2010; 2: a003004.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFonc2013565_CR59","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1182\/blood-2008-12-192583","volume":"114","author":"Z Li","year":"2009","unstructured":"Li Z, Wang H, Xue L, Shin DM, Roopenian D, Xu W et al. Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma. Blood 2009; 114: 4158\u20134168.","journal-title":"Blood"},{"key":"BFonc2013565_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2559.2010.03699.x","volume":"58","author":"MQ Du","year":"2011","unstructured":"Du MQ . MALT lymphoma: many roads lead to nuclear factor-kappab activation. Histopathology 2011; 58: 26\u201338.","journal-title":"Histopathology"},{"key":"BFonc2013565_CR61","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","volume":"101","author":"B Streubel","year":"2003","unstructured":"Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335\u20132339.","journal-title":"Blood"},{"key":"BFonc2013565_CR62","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1182\/blood-2002-10-3236","volume":"101","author":"D Sanchez-Izquierdo","year":"2003","unstructured":"Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J, Karran L et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 2003; 101: 4539\u20134546.","journal-title":"Blood"},{"key":"BFonc2013565_CR63","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ni1568","volume":"9","author":"F Rebeaud","year":"2008","unstructured":"Rebeaud F, Hailfinger S, Posevitz-Fejfar A, Tapernoux M, Moser R, Rueda D et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol 2008; 9: 272\u2013281.","journal-title":"Nat Immunol"},{"key":"BFonc2013565_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/ni1561","volume":"9","author":"B Coornaert","year":"2008","unstructured":"Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008; 9: 263\u2013271.","journal-title":"Nat Immunol"},{"key":"BFonc2013565_CR65","doi-asserted-by":"publisher","first-page":"14596","DOI":"10.1073\/pnas.1105020108","volume":"108","author":"S Hailfinger","year":"2011","unstructured":"Hailfinger S, Nogai H, Pelzer C, Jaworski M, Cabalzar K, Charton JE et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci USA 2011; 108: 14596\u201314601.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR66","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2013.04.034","volume":"153","author":"T Uehata","year":"2013","unstructured":"Uehata T, Iwasaki H, Vandenbon A, Matsushita K, Hernandez-Cuellar E, Kuniyoshi K et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell 2013; 153: 1036\u20131049.","journal-title":"Cell"},{"key":"BFonc2013565_CR67","first-page":"961","volume":"6","author":"AG Uren","year":"2000","unstructured":"Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell 2000; 6: 961\u2013967.","journal-title":"Mol Cell"},{"key":"BFonc2013565_CR68","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2217\/fon.11.35","volume":"7","author":"S Rosebeck","year":"2011","unstructured":"Rosebeck S, Lucas PC, McAllister-Lucas LM . Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol 2011; 7: 613\u2013617.","journal-title":"Future Oncol"},{"key":"BFonc2013565_CR69","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cellsig.2009.09.033","volume":"22","author":"LM Kingeter","year":"2010","unstructured":"Kingeter LM, Schaefer BC . Malt1 and cIAP2-Malt1 as effectors of NF-kappaB activation: kissing cousins or distant relatives? Cell Signal 2010; 22: 9\u201322.","journal-title":"Cell Signal"},{"key":"BFonc2013565_CR70","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1084\/jem.20091167","volume":"206","author":"U Ferch","year":"2009","unstructured":"Ferch U, Kloo B, Gewies A, Pfander V, Duwel M, Peschel C et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2009; 206: 2313\u20132320.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR71","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2004-06-2297","volume":"105","author":"L Ho","year":"2005","unstructured":"Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Mhawech P et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005; 105: 2891\u20132899.","journal-title":"Blood"},{"key":"BFonc2013565_CR72","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1073\/pnas.1204127109","volume":"109","author":"C Vicente-Duenas","year":"2012","unstructured":"Vicente-Duenas C, Fontan L, Gonzalez-Herrero I, Romero-Camarero I, Segura V, Aznar MA et al. Expression of MALT1 oncogene in hematopoietic stem\/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc Natl Acad USA 2012; 109: 10534\u201310539.","journal-title":"Proc Natl Acad USA"},{"key":"BFonc2013565_CR73","first-page":"3944","volume":"57","author":"G Ott","year":"1997","unstructured":"Ott G, Katzenberger T, Greiner A, Kalla J, Rosenwald A, Heinrich U et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997; 57: 3944\u20133948.","journal-title":"Cancer Res"},{"key":"BFonc2013565_CR74","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1038\/sj.onc.1203018","volume":"18","author":"T Akagi","year":"1999","unstructured":"Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785\u20135794.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR75","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2002-11-3502","volume":"102","author":"H Ye","year":"2003","unstructured":"Ye H, Liu H, Attygalle A, Wotherspoon AC, Nicholson AG, Charlotte F et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003; 102: 1012\u20131018.","journal-title":"Blood"},{"key":"BFonc2013565_CR76","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S0002-9440(10)65012-2","volume":"156","author":"M Baens","year":"2000","unstructured":"Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C . The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am JPathol 2000; 156: 1433\u20131439.","journal-title":"Am JPathol"},{"key":"BFonc2013565_CR77","doi-asserted-by":"publisher","first-page":"5270","DOI":"10.1158\/0008-5472.CAN-05-4590","volume":"66","author":"M Baens","year":"2006","unstructured":"Baens M, Fevery S, Sagaert X, Noels H, Hagens S, Broeckx V et al. Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IkappaB kinase gamma polyubiquitination. Cancer Res 2006; 66: 5270\u20135277.","journal-title":"Cancer Res"},{"key":"BFonc2013565_CR78","doi-asserted-by":"publisher","first-page":"e1000518","DOI":"10.1371\/journal.pbio.1000518","volume":"8","author":"DB Conze","year":"2010","unstructured":"Conze DB, Zhao Y, Ashwell JD . Non-canonical NF-kappaB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2. PLoS Biology 2010; 8: e1000518.","journal-title":"PLoS Biology"},{"key":"BFonc2013565_CR79","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1038\/sj.onc.1210342","volume":"26","author":"PC Lucas","year":"2007","unstructured":"Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K et al. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 2007; 26: 5643\u20135654.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR80","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/onc.2009.17","volume":"28","author":"JB Garrison","year":"2009","unstructured":"Garrison JB, Samuel T, Reed JC . TRAF2-binding BIR1 domain of c-IAP2\/MALT1 fusion protein is essential for activation of NF-kappaB. Oncogene 2009; 28: 1584\u20131593.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR81","doi-asserted-by":"publisher","first-page":"10180","DOI":"10.1074\/jbc.M611038200","volume":"282","author":"H Noels","year":"2007","unstructured":"Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P et al. A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions. J Biol Chem 2007; 282: 10180\u201310189.","journal-title":"J Biol Chem"},{"issue":"19","key":"BFonc2013565_CR82","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/onc.2013.195","volume":"33","author":"S Rosebeck","year":"2013","unstructured":"Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA et al. The API2\u2013MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-\u03baB signaling. Oncogene (e-pub ahead of print 17 June 2013; doi: 10.1038\/onc.2013.195).","journal-title":"Oncogene"},{"key":"BFonc2013565_CR83","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1198946","volume":"331","author":"S Rosebeck","year":"2011","unstructured":"Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011; 331: 468\u2013472.","journal-title":"Science"},{"key":"BFonc2013565_CR84","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/emboj.2011.85","volume":"30","author":"J Staal","year":"2011","unstructured":"Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011; 30: 1742\u20131752.","journal-title":"EMBO J"},{"key":"BFonc2013565_CR85","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ccr.2012.11.002","volume":"22","author":"D Nagel","year":"2012","unstructured":"Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012; 22: 825\u2013837.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR86","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","volume":"22","author":"L Fontan","year":"2012","unstructured":"Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012; 22: 812\u2013824.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR87","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","volume":"87","author":"LM Staudt","year":"2005","unstructured":"Staudt LM, Dave S . The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163\u2013208.","journal-title":"Adv Immunol"},{"key":"BFonc2013565_CR88","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503\u2013511.","journal-title":"Nature"},{"key":"BFonc2013565_CR89","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1084\/jem.20031074","volume":"198","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851\u2013862.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR90","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313\u20132323.","journal-title":"N Engl J Med"},{"key":"BFonc2013565_CR91","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1182\/blood-2002-07-2215","volume":"101","author":"C Copie-Bergman","year":"2003","unstructured":"Copie-Bergman C, Boulland ML, Dehoulle C, Moller P, Farcet JP, Dyer MJ et al. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 2003; 101: 2756\u20132761.","journal-title":"Blood"},{"key":"BFonc2013565_CR92","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520\u201313525.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR93","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871\u20133879.","journal-title":"Blood"},{"key":"BFonc2013565_CR94","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/gcc.20420","volume":"46","author":"MA Weniger","year":"2007","unstructured":"Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007; 46: 406\u2013415.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2013565_CR95","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937\u20131947.","journal-title":"N Engl J Med"},{"key":"BFonc2013565_CR96","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1158\/1078-0432.CCR-04-1842","volume":"11","author":"LT Lam","year":"2005","unstructured":"Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28\u201340.","journal-title":"Clin Cancer Res"},{"key":"BFonc2013565_CR97","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861\u20131874.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR98","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccr.2010.10.030","volume":"18","author":"J Mandelbaum","year":"2010","unstructured":"Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010; 18: 568\u2013579.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR99","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ccr.2010.11.024","volume":"18","author":"DP Calado","year":"2010","unstructured":"Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 2010; 18: 580\u2013589.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR100","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88\u201392.","journal-title":"Nature"},{"key":"BFonc2013565_CR101","doi-asserted-by":"publisher","first-page":"20798","DOI":"10.1073\/pnas.0806491106","volume":"105","author":"LT Lam","year":"2008","unstructured":"Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W et al. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci USA 2008; 105: 20798\u201320803.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR102","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature04687","volume":"441","author":"VN Ngo","year":"2006","unstructured":"Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106\u2013110.","journal-title":"Nature"},{"key":"BFonc2013565_CR103","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.1205299110","volume":"110","author":"J Zhang","year":"2013","unstructured":"Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398\u20131403.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR104","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00748.x","volume":"228","author":"T Kurosaki","year":"2009","unstructured":"Kurosaki T, Hikida M . Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009; 228: 132\u2013148.","journal-title":"Immunol Rev"},{"key":"BFonc2013565_CR105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1074-7613(00)80554-3","volume":"8","author":"RJ Cornall","year":"1998","unstructured":"Cornall RJ, Cyster JG, Hibbs ML, Dunn AR, Otipoby KL, Clark EA et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998; 8: 497\u2013508.","journal-title":"Immunity"},{"key":"BFonc2013565_CR106","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.4049\/jimmunol.166.3.1507","volume":"166","author":"H Ma","year":"2001","unstructured":"Ma H, Yankee TM, Hu J, Asai DJ, Harrison ML, Geahlen RL . Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J Immunol 2001; 166: 1507\u20131516.","journal-title":"J Immunol"},{"key":"BFonc2013565_CR107","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676\u20131679.","journal-title":"Science"},{"key":"BFonc2013565_CR108","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830\u2013837.","journal-title":"Nat Genet"},{"key":"BFonc2013565_CR109","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/nri1944","volume":"6","author":"DJ Rawlings","year":"2006","unstructured":"Rawlings DJ, Sommer K, Moreno-Garcia ME . The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006; 6: 799\u2013812.","journal-title":"Nat Rev Immunol"},{"key":"BFonc2013565_CR110","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.1021\/bi101052d","volume":"49","author":"RL Lamason","year":"2010","unstructured":"Lamason RL, McCully RR, Lew SM, Pomerantz JL . Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry 2010; 49: 8240\u20138250.","journal-title":"Biochemistry"},{"key":"BFonc2013565_CR111","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-10-2525","volume":"71","author":"TL Naylor","year":"2011","unstructured":"Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011; 71: 2643\u20132653.","journal-title":"Cancer Res"},{"key":"BFonc2013565_CR112","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723\u2013737.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR113","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1084\/jem.20112744","volume":"209","author":"YS Jeelall","year":"2012","unstructured":"Jeelall YS, Wang JQ, Law HD, Domaschenz H, Fung HK, Kallies A et al. Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. J Exp Med 2012; 209: 1907\u20131917.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR114","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1084\/jem.20120831","volume":"209","author":"AL Snow","year":"2012","unstructured":"Snow AL, Xiao W, Stinson JR, Lu W, Chaigne-Delalande B, Zheng L et al. Congenital B cell lymphocytosis explained by novel germline CARD11 mutations. J Exp Med 2012; 209: 2247\u20132261.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR115","doi-asserted-by":"publisher","first-page":"19946","DOI":"10.1073\/pnas.0907511106","volume":"106","author":"S Hailfinger","year":"2009","unstructured":"Hailfinger S, Lenz G, Ngo V, Posvitz-Fejfar A, Rebeaud F, Guzzardi M et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2009; 106: 19946\u201319951.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR116","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ni.2540","volume":"14","author":"C Pelzer","year":"2013","unstructured":"Pelzer C, Cabalzar K, Wolf A, Gonzalez M, Lenz G, Thome M . The protease activity of the paracaspase MALT1 is controlled by monoubiquitination. Nat Immunol 2013; 14: 337\u2013345.","journal-title":"Nat Immunol"},{"key":"BFonc2013565_CR117","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1073\/pnas.1008969108","volume":"108","author":"B Kloo","year":"2011","unstructured":"Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2011; 108: 272\u2013277.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR118","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717\u2013721.","journal-title":"Nature"},{"key":"BFonc2013565_CR119","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2013-06-508028","volume":"122","author":"H Nogai","year":"2013","unstructured":"Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V et al. IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. Blood 2013; 122: 2242\u20132250.","journal-title":"Blood"},{"key":"BFonc2013565_CR120","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115\u2013119.","journal-title":"Nature"},{"key":"BFonc2013565_CR121","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701\u20133713.","journal-title":"Blood"},{"key":"BFonc2013565_CR122","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","volume":"109","author":"JG Lohr","year":"2012","unstructured":"Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879\u20133884.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013565_CR123","first-page":"252318","volume":"2013","author":"G Troen","year":"2013","unstructured":"Troen G, Warsame A, J Delabie . CD79B and MYD88 Mutations in splenic marginal zone lymphoma. ISRN Oncol 2013; 2013: 252318.","journal-title":"ISRN Oncol"},{"key":"BFonc2013565_CR124","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ajh.23545","volume":"88","author":"S Poulain","year":"2013","unstructured":"Poulain S, Roumier C, Galiegue-Zouitina S, Daudignon A, Herbaux C, Aiijou R et al. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol 88: 948\u201354 2013.","journal-title":"Am J Hematol"},{"key":"BFonc2013565_CR125","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578\u20132585.","journal-title":"Blood"},{"key":"BFonc2013565_CR126","doi-asserted-by":"crossref","unstructured":"Wilson WH, Gerecitano JF, Goy A, de Vos S. The Bruton\u2019s tyrosine kinase inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo DLBCL: interim results of a multicenter, open-label, phase 2 study. 54th ASH Annual Meeting and Exposition; 8\u201311 December, 2012; Atlanta, GA, USA.","DOI":"10.1182\/blood.V120.21.686.686"},{"key":"BFonc2013565_CR127","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115\u2013130.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR128","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131\u2013144.","journal-title":"Cancer Cell"},{"key":"BFonc2013565_CR129","doi-asserted-by":"publisher","first-page":"e59127","DOI":"10.1371\/journal.pone.0059127","volume":"8","author":"F Cormier","year":"2013","unstructured":"Cormier F, Monjanel H, Fabre C, Billot K, Sapharikas E, Chereau F et al. Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. PloS One 2013; 8: e59127.","journal-title":"PloS One"},{"key":"BFonc2013565_CR130","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91\u201398.","journal-title":"J Exp Med"},{"key":"BFonc2013565_CR131","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021\u20131030.","journal-title":"Blood"},{"key":"BFonc2013565_CR132","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412\u20135417.","journal-title":"Blood"},{"key":"BFonc2013565_CR133","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","volume":"115","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM . Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010; 115: 3541\u20133552.","journal-title":"Blood"},{"key":"BFonc2013565_CR134","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1182\/blood.V84.11.3850.bloodjournal84113850","volume":"84","author":"A Migliazza","year":"1994","unstructured":"Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R et al. Heterogeneous chromosomal aberrations generate 3\u2032 truncations of the NFKB2\/lyt-10 gene in lymphoid malignancies. Blood 1994; 84: 3850\u20133860.","journal-title":"Blood"},{"key":"BFonc2013565_CR135","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","volume":"12","author":"T Hideshima","year":"2006","unstructured":"Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006; 12: 5887\u20135894.","journal-title":"Clin Cancer Res"},{"key":"BFonc2013565_CR136","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1365-2141.2007.06629.x","volume":"138","author":"M Jourdan","year":"2007","unstructured":"Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, Abouladze M et al. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 2007; 138: 160\u2013168.","journal-title":"Br J Haematol"},{"key":"BFonc2013565_CR137","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2004.08.009","volume":"21","author":"P Ramakrishnan","year":"2004","unstructured":"Ramakrishnan P, Wang W, Wallach D . Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 2004; 21: 477\u2013489.","journal-title":"Immunity"},{"key":"BFonc2013565_CR138","first-page":"2275","volume":"8","author":"M Naumann","year":"1993","unstructured":"Naumann M, Nieters A, Hatada EN, Scheidereit C . NF-kappa B precursor p100 inhibits nuclear translocation and DNA binding of NF-kappa B\/rel-factors. Oncogene 1993; 8: 2275\u20132281.","journal-title":"Oncogene"},{"key":"BFonc2013565_CR139","first-page":"6089","volume":"13","author":"RI Scheinman","year":"1993","unstructured":"Scheinman RI, Beg AA, Baldwin AS. Jr, NF-kappa B . p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol 1993; 13: 6089\u20136101.","journal-title":"Mol Cell Biol"},{"key":"BFonc2013565_CR140","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2006.12.033","volume":"128","author":"S Basak","year":"2007","unstructured":"Basak S, Kim H, Kearns JD, Tergaonkar V, O\u2019Dea E, Werner SL et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007; 128: 369\u2013381.","journal-title":"Cell"},{"key":"BFonc2013565_CR141","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947\u2013959.","journal-title":"Blood"},{"key":"BFonc2013565_CR142","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/MOH.0b013e328302c7f4","volume":"15","author":"ZW Li","year":"2008","unstructured":"Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR . NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008; 15: 391\u2013399.","journal-title":"Curr Opin Hematol"},{"key":"BFonc2013565_CR143","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3324\/haematol.2011.043331","volume":"97","author":"SC Ling","year":"2012","unstructured":"Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 2012; 97: 64\u201372.","journal-title":"Haematologica"},{"key":"BFonc2013565_CR144","doi-asserted-by":"publisher","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510\u201311519.","journal-title":"Cancer Res"},{"key":"BFonc2013565_CR145","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.bmcl.2013.01.012","volume":"23","author":"K Li","year":"2013","unstructured":"Li K, McGee LR, Fisher B, Sudom A, Liu J, Rubenstein SM et al. Inhibiting NF-kappaB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures. Bioorg Med Chem Lett 2013; 23: 1238\u20131244.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFonc2013565_CR146","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1016\/j.bmcl.2010.06.027","volume":"20","author":"J Mortier","year":"2010","unstructured":"Mortier J, Masereel B, Remouchamps C, Ganeff C, Piette J, Frederick R . NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. Bioorg Med Chem Lett 2010; 20: 4515\u20134520.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFonc2013565_CR147","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-12-0779","volume":"18","author":"C Fabre","year":"2012","unstructured":"Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D et al. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012; 18: 4669\u20134681.","journal-title":"Clin Cancer Res"},{"key":"BFonc2013565_CR148","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/sj.leu.2404919","volume":"21","author":"S Wessendorf","year":"2007","unstructured":"Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 2007; 21: 2463\u20132469.","journal-title":"Leukemia"},{"key":"BFonc2013565_CR149","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/gcc.20495","volume":"46","author":"LR Kimm","year":"2007","unstructured":"Kimm LR, deLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J et al. Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer 2007; 46: 1090\u20131097.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2013565_CR150","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2141.2004.05000.x","volume":"126","author":"RK Thomas","year":"2004","unstructured":"Thomas RK, Wickenhauser C, Tawadros S, Diehl V, Kuppers R, Wolf J et al. Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma. Br J Haematol 2004; 126: 50\u201354.","journal-title":"Br J Haematol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2013565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2013565","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2013565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T17:39:04Z","timestamp":1716485944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2013565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":150,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2014,12,11]]}},"alternative-id":["BFonc2013565"],"URL":"https:\/\/doi.org\/10.1038\/onc.2013.565","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]},"assertion":[{"value":"16 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}